Zymeworks — Third Quarter 2026 Earnings Summary

Zymeworks reported a net income of $173.7 million for the third quarter of 2026, driven primarily by a $250 million milestone payment from Jazz Pharmaceuticals following the U.S. FDA approval of Ziihera for first-line gastroesophageal adenocarcinoma. The company raised its full-year 2026 financial guidance to a total revenue range of $337 million to $351 million and an Adjusted EBITDA range of $176 million to $190 million. Strategic developments include the acquisition of Theravance Biopharma, which added recurring revenue from YUPELRI, and a new global collaboration with Roche for the ZW209 program. Additionally, Zymeworks repurchased over 534,000 shares in the quarter and plans to host an R&D Day in New York on February 11, 2027.